Focus on knowledge creation

Without ideas there is nothing to manage

Synapse is the amypad_logoproject manager for the AMYPAD project (Amyloid imaging to prevent Alzheimer’s disease), kicked-off on October 5-6, 2016 in London, which will investigate the value of β-amyloid using positron emission tomography (PET) imaging as a diagnostic and therapeutic marker for Alzheimer’s dementia.
Beta-amyloid (β-amyloid) deposition in the brain is one of the neuropathological hallmarks on the path towards development of Alzheimer’s disease (AD). The recent advent of commercially available β-amyloid PET tracers has opened up new potential for the visualisation of brain β-amyloid in vivo. It may improve an early diagnosis of AD, and, when recognised in a pre-symptomatic population, even provide an opportunity for secondary prevention of AD. However, the full value of this relatively novel technology and its optimal position in the diagnostic workup of patients is not yet fully understood.
AMYPAD will determine in a real-life clinical setting for whom diagnostic β-amyloid imaging is appropriate, when this is best performed and how the resulting information is influencing diagnostic certainty, patient management and ultimately decision trees and cost-effectiveness of dementia care.
The AMYPAD consortium (15 public and private organisations formed by academic institutions, pharmaceutical companies, SMEs and patient organisations) will address the above goals in close collaboration with IMI-JU project EPAD (European prevention of Alzheimer’s dementia |, a major global initiative, also managed by Synapse, to create a novel environment for testing new treatments for the prevention of Alzheimer’s dementia.
The project is led by GE Healthcare Life Sciences and coordinated by VU University Medical Center, Amsterdam. Synapse is member of the Executive Committee, leads the Project Management work package, and is involved in the design and implementation of dissemination plans and communication strategy within WP6 (Ethics, communication and dissemination) activities.
AMYPAD is mainly sponsored by the European Union’s Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative 2 Joint Undertaking (
For more information, contact, check out or follow @IMI_AMYPAD on Twitter.